ELOQUENT-2 trial of elotuzumab plus lenalidomide/dexamethasone in multiple myeloma

Sagar Lonial

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses the results of the randomized, open-label, phase 3 ELOQUENT-2 trial of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma.

Subject:

Multiple Myeloma

Medicines:

Elotuzumab

Event:

EHA 2015

Recorded:

2nd June 2015